secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001125345-25-000043
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics reports FY2024 net loss of $67M; discontinues vobra duo development
-------------------------------------------------------------------------------

- Net loss of $67.0M ($1.07 diluted EPS) for FY2024 vs. net loss of $9.1M ($0.15) in FY2023.
- Total revenue $150.0M, up from $58.7M in FY2023, driven by $85M milestone from Incyte.
- Cash, cash equivalents and marketable securities $201.7M at Dec 31, 2024; cash runway extended into H2 2026.
- Discontinuing further internal development of vobra duo; seeking partner; Phase 2 TAMARACK rPFS 9.5-10.0 months.
- LORIKEET Phase 2 fully enrolled (150 patients); LINNET Phase 2 in ovarian cancer expected mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534525000043/0001125345-25-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534525000043/mgnx-20250320.htm
  HTML page:      https://secwatch.observer/filing/0001125345-25-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer